RxDoctor Payments Data

Vahagn Zakaryan, MD

Nephrology · Grove City, OHNPI 1245597038

Payments from drug & device makers

$890in general payments, 2019–2025

Across 26 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$253
  • Amgen$147
  • Aurinia Pharma U.S., Inc.$123
  • Medtronic$89
  • Otsuka America Pharmaceutical, Inc.$75
  • BD$61
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$85696%
  • Education$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890 in reported general payments places this provider in the 40th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$138,316
Medicare patients
351
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol155$135,242
VelphoroSucroferric Oxyhydroxide32$113,377
KerendiaFinerenone74$89,173
JardianceEmpagliflozin35$40,242
EliquisApixaban13$16,343
LokelmaSodium Zirconium Cyclosilicate27$14,700
Sevelamer Carbonate49$14,397
Cinacalcet Hcl13$6,169
Telmisartan75$3,359
Allopurinol173$2,172
Chlorthalidone138$2,117
Calcitriol52$1,425
Calcium Acetate11$1,113
Doxazosin Mesylate39$1,053
Famotidine71$994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$253$149,942182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 nephrology providers in Ohio.

Other nephrology in Grove City

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →